SIETES :: 92571 citas

Resultados de la búsqueda por OXICODONA REFINAR BÚSQUEDA

1.

Hider-Mlynarz K, Cavalié P, Maison P. Trends in analgesic consumption in France over the last 10 years and comparison of patterns across Europe. Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102806]

2.

Floyd CN, Warren JB. Opioids out of control. Br J Clin Pharmacol 2018;84:mayo. [Ref.ID 102794]

3.

Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee ostoarthritis pain. The SPACE randomized clinical trial. JAMA 2018;319:6 de marzo. [Ref.ID 102554]

4.

Moore PA, Ziegler KM, Lipman RD, Aminoshariae A, Carrasco-Labra A, Mariotti A. Benefits and harms associated with analgesic medications used in the management of acute dental pain. The Journal of the American Dental Association 2018;149:abril. [Ref.ID 102481]

5.

Anónimo. Senate investigation reveals five manufacturers funded groups that acted as opioid “cheerleaders.”. DIA Daily 2018:12. [Ref.ID 102455]

6.

Anónimo. Purdue to halt OxyContin promotional visits with physicians, cut sales force by half. DIA Daily 2018:16. [Ref.ID 102453]

7.

Mir de Francia R. Los fabricantes de opioides fijan a España como nuevo mercado. eldiario.es 2018:1. [Ref.ID 102452]

8.

Haffajee RL, Mello MM. Drug companies’ liability for the opioid epidemic. N Engl J Med 2017;377:2301-5. [Ref.ID 102168]

9.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

10.

Chang AK, Bijur PE, Esses D, Barnaby DP, Baer J. Effect of a single dose of oral opioid and nonopioid analgesics on acute extremity pain in the emergency department. A randomized clinical trial. JAMA 2017;318:1661-7. [Ref.ID 102137]

11.

Kyriacou DN. Opioid vs nonopioid acute pain management in the emergency department. JAMA 2017;318:1655-6. [Ref.ID 102136]

12.

Vélez AM. Juan Abelló pone a la venta su monopolio del opio en pleno debate sobre su venta descontrolada en EEUU . eldiario.es 2017:1. [Ref.ID 102121]

13.

Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ 2017;359:j4792. [Ref.ID 102106]

14.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

15.

Armstrong D. Kentucky Senate president urges release of secret OxyContin records. STAT 2017:28 de junio. [Ref.ID 101657]

16.

Becker WC, Fiellin DA. Abuse-deterrent opioid formulations - Putting the potential benefits into perspective. N Engl J Med 2017;376:2103-5. [Ref.ID 101625]

17.

Anónimo. Congressional representatives warn WHO of Purdue Pharma’s global push. DIA Daily 2017:3. [Ref.ID 101563]

18.

Anónimo. Litigation is new tactic in opioid crisis. DIA Daily 2017:1. [Ref.ID 101500]

19.

Welch WVa. Secret trove reveals bold ‘crusade’ to make OxyContin a blockbuster. STAT 2016:1. [Ref.ID 100698]

20.

Shaheed CA, Maher CG, Williams KA, Day R, McLachlan AJ. Efficacy, tolerability, and dose-dependent effects of opioid analgesics for low back pain: a systematic review and meta-analysis. JAMA Intern Med 2016;176:958-68. [Ref.ID 100298]